-
1
Cell-extrinsic hematopoietic impact of Ezh2 inactivation in fetal liver endothelial cells
Published 2018“…American Society of Hematology…”
Journal article -
2
Niche heterogeneity impacts evolution of myeloproliferative neoplasms driven by the same oncogenic pathway
Published 2018“…American Society of Hematology…”
Conference item -
3
Longitudinal mutational analysis in hydroxycarbamide-resistant/intolerant essential thrombocythemia treated on the majic-ET study
Published 2018“…American Society of Hematology…”
Conference item -
4
Correlation between treatment outcomes, baseline characteristics and molecular responses in the Majic study which compared Ruxolitinib to best available therapy in essential thromb...
Published 2016“…American Society of Hematology…”
Conference item -
5
A single-cell approach to unraveling abnormal megakaryocyte differentiation and function in myelofibrosis
Published 2017“…American Society of Hematology…”
Conference item -
6
Canonical Notch signaling is dispensible for adult steady-state and stress myelo-erythropoiesis
Published 2018“…American Society of Hematology…”
Journal article -
7
Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
Published 2018“…American Society of Hematology…”
Conference item -
8
Discovery of a CD10 negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs
Published 2019“…American Society of Hematology…”
Journal article -
9
Molecular and Functional Characterization of Disease-Propagating Stem Cells in Juvenile Myelomonocytic Leukemia
Published 2017“…American Society of Hematology…”
Conference item -
10
Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation
Published 2019“…American Society of Hematology…”
Journal article -
11
Cell-Intrinsic Depletion of AML1-ETO-Positive Pre-Leukemic HSCs By Kras Activating Mutation
Published 2017“…American Society of Hematology…”
Conference item -
12
Myeloproliferative neoplasm stem cells
Published 2017“…American Society of Hematology…”
Journal article -
13
Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial
Published 2017“…American Society of Hematology…”
Journal article